Trubrexa Patch ER .00025 g/g
Trubrexa Patch ER · PATCH · Direct_Rx
Trubrexa Patch ER is a patch containing trubrexa patch er at .00025 g/g, taken transdermal. Manufactured by Direct_Rx.
Key Facts
- Brand Name
- Trubrexa Patch ER
- Generic Name
- Trubrexa Patch ER
- NDC Code (Product)
72189-541- Manufacturer
- Direct_Rx
- Strength
- .00025 g/g
- Dosage Form
- PATCH
- Route
- TRANSDERMAL
- Marketing Status
- Drug Class
- Amide Local Anesthetic [EPC]; Antiarrhythmic [EPC]
- Marketing Start
- 03/11/2024
Recall History
No Recall HistoryFull Prescribing Information
Indications & Usage
Trubrexa TM Transdermal Patch is indicated in adults over the age of 12 years old for the treatment of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more.
Dosage & Administration
2.1 Important Dosage and Administration Instructions Unintended exposure to capsaicin can cause severe irritation of the eyes, mucous membranes, respiratory tract, and skin in healthcare providers and others. Because unintended exposure to capsaicin can cause severe irritation of eyes, mucous membranes, respiratory tract, and skin, when administering Trubrexa TM Transdermal Patch it is important to follow these procedures: Keep Trubrexa TM Transdermal Patch in the sealed pouch until immediately before use. Use Trubrexa TM Transdermal Patch only on dry, intact (unbroken) skin. During administration, avoid unnecessary contact with any items in the room, including items that the patient may later have contact with, such as horizontal surfaces and bedsheets. Immediately after use, clean all areas of skin that had contact with Trubrexa TM Transdermal Patch. Ensure all used and unused pieces Trubrexa TM Transdermal Patch are properly disposed of. 2.2 Dosing and Instructions for Use Tear open pouch bag and remove one patch. Place remaining patches back in pouch bag and seal the pouch bag closed. Peel the clear plastic film away and apply Trubrexa TM Transdermal Patch to intact skin to cov…
Contraindications
Trubrexa TM Transdermal Patch is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
Drug Interactions
Antiarrhythmic Drugs Trubrexa TM Transdermal Patch should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When Trubrexa TM Transdermal Patch is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered. Drugs That May Cause Methemoglobinemia Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Nitrates/Nitrites (nitric oxide, nitroglycerin, nitroprusside, nitrous oxide) Local anesthetics (benzocaine, bupivacaine, lidocaine, prilocaine, procaine, tetracaine) Antineoplastic Agents (cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase) Antibiotics (dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides) Antimalarials (chloroquine, primaquine) Anticonvulsants (Phenobarbital, phenytoin, sodium valproate) Other Drugs (acetaminophen, metoclopramide, quinine, sulfasalazine)
Adverse Reactions
5.1 Risk of Methemoglobinemia Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; fatigue; or lightheadedness. Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by cyanotic skin discoloration and/or abnormal coloration of the …
Frequently Asked Questions
What is Trubrexa Patch ER used for?
Trubrexa Patch ER contains Trubrexa Patch ER. It is a patch taken transdermal. Consult your doctor for specific uses.
Is Trubrexa Patch ER a controlled substance?
Trubrexa Patch ER is not classified as a controlled substance by the DEA.
What is the generic name for Trubrexa Patch ER?
The generic name for Trubrexa Patch ER is Trubrexa Patch ER. There are no other listed brand versions of Trubrexa Patch ER.
What is the NDC code for Trubrexa Patch ER .00025 g/g?
The NDC (National Drug Code) for Trubrexa Patch ER .00025 g/g is 72189-541, listed by Direct_Rx.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)